KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Accumulated Expenses: 2017-2020

Historic Other Accumulated Expenses for Aquestive Therapeutics (AQST) over the last 4 years, with Dec 2020 value amounting to $201,000.

  • Aquestive Therapeutics' Other Accumulated Expenses fell 17.28% to $201,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $201,000, marking a year-over-year decrease of 17.28%. This contributed to the annual value of $201,000 for FY2020, which is 17.28% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Other Accumulated Expenses stood at $201,000 for FY2020, which was down 17.28% from $243,000 recorded in FY2019.
  • In the past 5 years, Aquestive Therapeutics' Other Accumulated Expenses ranged from a high of $243,000 in FY2019 and a low of $201,000 during FY2020.
  • Over the past 3 years, Aquestive Therapeutics' median Other Accumulated Expenses value was $207,000 (recorded in 2018), while the average stood at $217,000.
  • In the last 5 years, Aquestive Therapeutics' Other Accumulated Expenses climbed by 17.39% in 2019 and then declined by 17.28% in 2020.
  • Over the past 4 years, Aquestive Therapeutics' Other Accumulated Expenses (Yearly) stood at $225,000 in 2017, then fell by 8.00% to $207,000 in 2018, then rose by 17.39% to $243,000 in 2019, then declined by 17.28% to $201,000 in 2020.